BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, January 17, 2026
Home » Authors » Brady Huggett

Brady Huggett

Articles

ARTICLES

Biopure’s Stock Rises on Blood Substitute Phase III Study Data

March 21, 2002
By Brady Huggett

Paion To Develop Millennium’s MLN519 Cardiovascular Product

March 15, 2002
By Brady Huggett
Millennium Pharmaceuticals Inc. decided to let someone else drive, or at least pay for the gas, in the development of its cardiovascular product, MLN519. (BioWorld Today)
Read More

Paion To Develop Millennium’s MLN519 Cardiovascular Product

March 15, 2002
By Brady Huggett
Millennium Pharmaceuticals Inc. decided to let someone else drive, or at least pay for the gas, in the development of its cardiovascular product, MLN519. (BioWorld Today)
Read More

MitoKor Eyes Public Markets, Files For Estimated $60M IPO

March 12, 2002
By Brady Huggett

MitoKor Eyes Public Markets, Files For Estimated $60M IPO

March 12, 2002
By Brady Huggett

Celgene Changing Course On Thalomid In Multiple Myeloma

March 8, 2002
By Brady Huggett
Celgene Corp. is facing a delay in its new drug application for Thalomid after the FDA said it had to conduct a new trial in a different indication, but one that may be more lucrative over time. (BioWorld Today)
Read More

Celgene Changing Course On Thalomid In Multiple Myeloma

March 8, 2002
By Brady Huggett
Celgene Corp. is facing a delay in its new drug application for Thalomid after the FDA said it had to conduct a new trial in a different indication, but one that may be more lucrative over time. (BioWorld Today)
Read More

Centocor’s Remicade Receives Third Rheumatoid Arthritis Nod

March 1, 2002
By Brady Huggett
Centocor Inc.’s Remicade is inflating - both in uses and sales - having received a third approval in a rheumatoid arthritis indication. (BioWorld Today)
Read More

Centocor’s Remicade Receives Third Rheumatoid Arthritis Nod

March 1, 2002
By Brady Huggett
Centocor Inc.’s Remicade is inflating - both in uses and sales - having received a third approval in a rheumatoid arthritis indication. (BioWorld Today)
Read More

ImClone Says FDA Might Accept Erbitux BLA With No New Trials

Feb. 28, 2002
By Brady Huggett
ImClone Systems Inc., after being dragged to scandalous depths not often seen in the biotechnology sector, bobbed to the surface Wednesday following its meeting with the FDA concerning the cancer drug Erbitux. (BioWorld Today)
Read More
View All Articles by Brady Huggett

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 16, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 16, 2026.
  • SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

    BioWorld Science
    Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
  • Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

    BioWorld
    With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
  • Businesswoman pressing dollar sign on touchscreen

    JPM 2026: Year kicks off with biopharma Q4 revenue and guidance

    BioWorld
    It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing